Walsh, G., Murphy, B. (Eds.)

1999, X, 514 p.

Hardcover

Content Level » Research

TABLE OF CONTENTS :

Contributors.

Acknowledgements.

Preface.

Biopharmaceuticals, an overview; G. Walsh.

Abciximab: The First Platelet Glycoprotein IIb/IIIa Receptor Antagonist; R.E. Jordan, et al.

Recombinant Coagulation Factor IX (BeneFix®); J. Edwards, N. Kirby.

Biopharmaceutical Drug Development: A Case History; M. Foote, T. Boone. Follitropin beta (Puregon); H.J. Out.

Insulin Lispro (Humalog); R.E. Chance, et al.

Interferon beta-1b - the first long-term effective treatment of relapsing-remitting and secondary progressive multiple sclerosis (MS); R. Horowski, et al.

Reteplase, a recombinant Plasminogen activator; M. Waller, U. Kohnert.

Stabilisation of biopharmaceutical products and finished product formulations; M.S. Hora, B.-L. Chen.

Patent Law for Biopharmaceuticals; R.S. Crespi.

The development of new medicines: an overview; J.C. Stinson.

The EMEA and regulatory control of (bio)pharmaceuticals within the European Union; G. Walsh.

Biopharmaceutical Validation: an overview; S. Slater.

Validation of Biopharmaceutical Chromatography Systems; K.F. Williams, C.J.A. Davids.

Validation of Water for Injections (WFI) for Biopharmaceutical Manufacture; P. Baker, W. Allan.

Information retrieval and the biopharmaceutical industry: an introductory overview; P. O'Donnell.

Information technology and the internet as a resource of biopharmaceutical information; J.P. Jenuth, et al.

Marketing Issues for the (Bio)pharmaceutical sector; S. Spinka.

Viral mediated gene therapy; B. Murphy.

Pharmaceutical gene medicines for non-viral gene therapy; A. Rolland, et al.

Index.